Taking notes from MD Anderson and Rice University, Avenge Bio uncloaks with $45M and a slate of immunotherapies

Nicole DeFeudis

Editor

Michael Heffernan was already the head of a biotech company focused on chronic pain, called Collegium Pharmaceutical, which he successfully brought public in 2015. But …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Taking notes from MD Anderson and Rice University, Avenge Bio uncloaks with $45M and a slate of immunotherapies

Nicole DeFeudis

Editor

Sign up to read this article for free.

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

Post-Hoc: Pharma CEOs' alternative reality with Trump

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

FDA lifts hold on Entrada's Duchenne drug after two years

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

How AI can address ongoing challenges in the life sciences industry

Tak­ing notes from MD An­der­son and Rice Uni­ver­si­ty, Avenge Bio un­cloaks with $45M and a slate of im­munother­a­pies

Nicole DeFeudis

Editor

Sign up to read this article for free.

Pfiz­er hires ex-FDA deputy Pa­trizia Cavaz­zoni as chief med­ical of­fi­cer

Post-Hoc: Phar­ma CEOs' al­ter­na­tive re­al­i­ty with Trump

Pfiz­er wants in on Sum­mit’s goal to beat Keytru­da via ADC com­bos

FDA lifts hold on En­trada's Duchenne drug af­ter two years

Sanofi, Te­va bol­ster case for IBD drug with Phase 2 da­ta, de­spite po­ten­tial com­pe­ti­tion

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

Taking notes from MD Anderson and Rice University, Avenge Bio uncloaks with $45M and a slate of immunotherapies

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

Post-Hoc: Pharma CEOs' alternative reality with Trump

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

FDA lifts hold on Entrada's Duchenne drug after two years

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

How AI can address ongoing challenges in the life sciences industry